China is the “Innovation Nation” and “The next biotech superpower”, according to the November issue of Nature Biotechnology. Beijing is “set to challenge the pre-eminence of the US drug market. If it can address gaps in its R&D ecosystem and clinical infrastructure, it may even become a home for biotech innovators”, says the editorial.Continue reading
Great piece of science by the Liu Lab in Nature, describing the brand new “Search-and-replace genome editing without double-strand breaks or donor DNA”. How is the CRISPR community reacting?
Best quote: “One of those ‘Yay, science!!!’ kind of moments” (Fyodor Urnov quoted in Science)
Most ironic: “Congratulations @davidrliu. We’d probably have published this paper as well (The CRISPR Journal tweet)
Best title: Genome Editing Heads to Primetime (Genetic Engineering and Biotechnology News)
Most understated: A New Gene Editing Tool Could Make CRISPR More Precise (Smithsonian Mag)
Most hyped: A New CRISPR Technique Could Fix Almost All Genetic Diseases (Wired)
The ethics of using CRISPR to improve the odds of savior siblings. This is when a couple tries to have another baby who is both healthy and a suitable donor “match” for their older kid (“Could editing the DNA of embryos with CRISPR help save people who are already alive?“, STAT News, Sept. 16).
Carl Zimmer explaining a CRISPR experiment carried out to understand why many cancer drugs fail (“Why Aren’t Cancer Drugs Better? The Targets Might Be Wrong”, New York Times, Sept. 11; see also the paper in Science Translational Medicine)
While many of us have been enjoying a bit of holiday rest, CRISPR never stopped cutting DNA.
It did it inside smart gels, releasing biomolecules at command and turning electronic circuits into diagnostic devices (see the paper in Science and the news in Nature). It did in the bacterial genome, by manipulating large chunks of chromosomes as hoped for by synthetic biologists (see Science). It did it in the Mediterranean fruit fly to unveil sex-determination signals (see Science again) and is busy doing it in sheep to fight lethal child brain disease (as reported by The Guardian). Let’s catch up with the latest CRISPR news!
Doudna meets GSK: University of California CRISPR researchers form drug discovery alliance with pharma giant (source Science)
From transposons to gene therapy: Hijack of CRISPR defences by selfish genes holds clinical promise, according to Fyodor Urnov (Nature News&Views)
Disaster waiting to happen: Russian biologist plans more CRISPR-edited babies (Nature’s editorial and news)
“Wow! Badass. 13,200 crispr base edits in a single cell! On the way to ‘recoded’ human cells,” tweeted Antonio Regalado before covering the news in MIT Technology Review. To be honest, the radical redesign of species is still sci-fi dystopia, but the paper preprinted by Cory J. Smith et al. in bioRxiv is impressive anyway. Continue reading
Where is Jennifer Doudna? This is the first thought most journalists had – me included – when reading the list of signatories to the call for the moratorium on heritable genome editing just published by Nature. The Boston team is well represented by Lander, Zhang and Liu (nobody would expect George Church to join that call). But the magnificent couple Doudna-Charpentier has conspicuously split up. Continue reading